Rational repurposing, synthesis, in vitro and in silico studies of chromone-peptidyl hybrids as potential agents against Leishmania donovani

Abstract A chromone-peptidyl hybrids series was synthesised and rationally repurposed towards identification of potential antileishmanial hits against visceral leishmaniasis. Three hybrids 7c, 7n, and 7h showed potential IC50 values (9.8, 10, and 12 µM, respectively) which were comparable to erufosine IC50 (9.8 µM) but lower potency than miltefosine IC50 (3.5 µM). Preliminary assessment of cytotoxicity using human THP-1 cells presented chromone-peptidyl hybrids 7c and 7n as non-cytotoxic up to 100 µM while erufosine and miltefosine had CC50 of 19.4 µM and >40 µM, respectively. In silico studies pinpointed the N-p-methoxyphenethyl substituent at the peptidyl moiety together with the oxygen-based substituted functions of the phenyl ring of the chromone moiety as crucial players in binding to LdCALP. Together, these findings present chromone-peptidyl hybrids 7c and 7n as potential and anticipated non-cytotoxic antileishmanial hit compounds for possible development of potential antileishmanial agents against visceral leishmaniasis.

[1]  Jong-Hyun Park,et al.  Synthesis and Biological Evaluation of O6-Aminoalkyl-Hispidol Analogs as Multifunctional Monoamine Oxidase-B Inhibitors towards Management of Neurodegenerative Diseases , 2023, Antioxidants.

[2]  E. Ricci-Júnior,et al.  Nanoparticles for the treatment of visceral leishmaniasis: review , 2023, Journal of Nanoparticle Research.

[3]  S. Robledo,et al.  A Biologically Active Chromone from Bomarea setacea ( alstroemeriaceae ): Leishmanicidal, Antioxidant and Multilevel Computational Studies , 2022, ChemistrySelect.

[4]  Kyung-Sook Chung,et al.  3',4'-Dihydroxyflavone mitigates inflammatory responses by inhibiting LPS and TLR4/MD2 interaction. , 2022, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[5]  D. Zama,et al.  Visceral Leishmaniasis: Epidemiology, Diagnosis, and Treatment Regimens in Different Geographical Areas with a Focus on Pediatrics , 2022, Microorganisms.

[6]  F. Tuon,et al.  Liposomal drug delivery systems for the treatment of leishmaniasis , 2022, Parasitology Research.

[7]  T. Phan,et al.  Design, Rational Repurposing, Synthesis, In Vitro Evaluation, Homology Modeling and In Silico Study of Sulfuretin Analogs as Potential Antileishmanial Hit Compounds , 2022, Pharmaceuticals.

[8]  Prof Vikas Kumar,et al.  - Amphotericin B: A drug of choice for Visceral Leishmaniasis. , 2022, Acta tropica.

[9]  E. Akl,et al.  Stakeholders’ views and perspectives on treatments of visceral leishmaniasis and their outcomes in HIV-coinfected patients in East Africa and South-East Asia: A mixed methods study , 2022, PLoS neglected tropical diseases.

[10]  F. Dumetz,et al.  Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis , 2022, Frontiers in Tropical Diseases.

[11]  Kyung-Sook Chung,et al.  Mosloflavone-Resveratrol Hybrid TMS-HDMF-5z Exhibits Potent In Vitro and In Vivo Anti-Inflammatory Effects Through NF-κB, AP-1, and JAK/STAT Inactivation , 2022, Frontiers in Pharmacology.

[12]  Ki Duk Park,et al.  Positional scanning of natural product hispidol’s ring-B: discovery of highly selective human monoamine oxidase-B inhibitor analogues downregulating neuroinflammation for management of neurodegenerative diseases , 2022, Journal of enzyme inhibition and medicinal chemistry.

[13]  N. Karunaweera,et al.  Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review , 2022, Infectious Diseases and Therapy.

[14]  Kyung-Sook Chung,et al.  AKF-D52, a Synthetic Phenoxypyrimidine-Urea Derivative, Triggers Extrinsic/Intrinsic Apoptosis and Cytoprotective Autophagy in Human Non-Small Cell Lung Cancer Cells , 2021, Cancers.

[15]  K. Yadav,et al.  Road map to the treatment of neglected tropical diseases: Nanocarriers interventions. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[16]  P. Rai,et al.  Drug repurposing based novel anti-leishmanial drug screening using in-silico and in-vitro approaches , 2021, Journal of biomolecular structure & dynamics.

[17]  Hongqiao Zhang,et al.  Targeting oxidative stress in disease: promise and limitations of antioxidant therapy , 2021, Nature Reviews Drug Discovery.

[18]  Mohammed A Alaidarous,et al.  Repurposing of FDA‐approved drugs as inhibitors of sterol C‐24 methyltransferase of Leishmania donovani to fight against leishmaniasis , 2021, Drug development research.

[19]  Marco Biasini,et al.  ProMod3—A versatile homology modelling toolbox , 2021, PLoS Comput. Biol..

[20]  Yong Sup Lee,et al.  Pyrrolidine-based 3-deoxysphingosylphosphorylcholine analogs as possible candidates against neglected tropical diseases (NTDs): identification of hit compounds towards development of potential treatment of Leishmania donovani , 2021, Journal of enzyme inhibition and medicinal chemistry.

[21]  P. Fernandes,et al.  Evolution of chromone-like compounds as potential antileishmanial agents, through the 21st century , 2020, Expert opinion on drug discovery.

[22]  Jaydeep Roy,et al.  Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II) , 2020, Journal of biomolecular structure & dynamics.

[23]  Kyung-Sook Chung,et al.  Diarylurea derivatives comprising 2,4-diarylpyrimidines: Discovery of novel potential anticancer agents via combined failed-ligands repurposing and molecular hybridization approaches. , 2020, Bioorganic chemistry.

[24]  R. Bureau,et al.  Drug repositioning: a brief overview , 2020, The Journal of pharmacy and pharmacology.

[25]  David Shum,et al.  In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei , 2020, Molecules.

[26]  Ki Duk Park,et al.  Reprofiling of pyrimidine-based DAPK1/CSF1R dual inhibitors: identification of 2,5-diamino-4-pyrimidinol derivatives as novel potential anticancer lead compounds , 2019, Journal of enzyme inhibition and medicinal chemistry.

[27]  S. Braga Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing. , 2019, European journal of medicinal chemistry.

[28]  Kyung-Sook Chung,et al.  The Anti-Proliferative Activity of the Hybrid TMS-TMF-4f Compound Against Human Cervical Cancer Involves Apoptosis Mediated by STAT3 Inactivation , 2019, Cancers.

[29]  Kyung-Tae Lee,et al.  Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: Discovery of novel p38-α MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators. , 2019, European journal of medicinal chemistry.

[30]  C. Nakamura,et al.  trans‐Chalcone modulates Leishmania amazonensis infection in vitro by Nrf2 overexpression affecting iron availability , 2019, European journal of pharmacology.

[31]  R. Casagrande,et al.  Quercetin promotes antipromastigote effect by increasing the ROS production and anti-amastigote by upregulating Nrf2/HO-1 expression, affecting iron availability. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[32]  Jongki Hong,et al.  Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids. , 2019, Bioorganic chemistry.

[33]  D. Murrell,et al.  Cutaneous leishmaniasis: A neglected disfiguring disease for women , 2019, International journal of women's dermatology.

[34]  Ji-Sun Shin,et al.  Natural products hybrids: 3,5,4'-Trimethoxystilbene-5,6,7-trimethoxyflavone chimeric analogs as potential cytotoxic agents against diverse human cancer cells. , 2019, European journal of medicinal chemistry.

[35]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[36]  S. Nixdorf,et al.  Caryocar coriaceum extracts exert leishmanicidal effect acting in promastigote forms by apoptosis-like mechanism and intracellular amastigotes by Nrf2/HO-1/ferritin dependent response and iron depletion: Leishmanicidal effect of Caryocar coriaceum leaf exracts. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[37]  L. B. de Arruda,et al.  The potent cell permeable calpain inhibitor MDL28170 affects the interaction of Leishmania amazonensis with macrophages and shows anti-amastigote activity. , 2017, Parasitology international.

[38]  Torsten Schwede,et al.  The SWISS-MODEL Repository—new features and functionality , 2016, Nucleic Acids Res..

[39]  Ariel Chernomoretz,et al.  A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases , 2016, PLoS neglected tropical diseases.

[40]  M. Dacher,et al.  Implication of different domains of the Leishmania major metacaspase in cell death and autophagy , 2015, Cell Death and Disease.

[41]  S. Robledo,et al.  Synthesis, Leishmanicidal and Cytotoxic Activity of Triclosan-Chalcone, Triclosan-Chromone and Triclosan-Coumarin Hybrids , 2014, Molecules.

[42]  Jim Euchner Design , 2014, Catalysis from A to Z.

[43]  T. Souto-Padrón,et al.  The Calpain Inhibitor MDL28170 Induces the Expression of Apoptotic Markers in Leishmania amazonensis Promastigotes , 2014, PloS one.

[44]  Branquinha Mh,et al.  Calpains: Potential Targets for Alternative Chemotherapeutic Intervention Against Human Pathogenic Trypanosomatids , 2013, Current medicinal chemistry.

[45]  S. Sundar,et al.  Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani , 2013, Parasitology Research.

[46]  J. Cano,et al.  Leishmaniasis Worldwide and Global Estimates of Its Incidence , 2012, PloS one.

[47]  S. Maiti,et al.  Protective Therapy with Novel Chromone Derivative against Leishmania donovani Infection Induces Th1 Response in vivo , 2011, Chemotherapy.

[48]  Seo Yun Jung,et al.  Synthesis of chromone carboxamide derivatives with antioxidative and calpain inhibitory properties. , 2011, European journal of medicinal chemistry.

[49]  G. H. Coombs,et al.  α‐Ketoheterocycles as Inhibitors of Leishmania mexicana Cysteine Protease CPB , 2010, ChemMedChem.

[50]  Yong Sup Lee,et al.  Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. , 2009, European journal of medicinal chemistry.

[51]  J. L. Martins,et al.  Antileishmanial activity of MDL 28170, a potent calpain inhibitor , 2006, International Journal of Antimicrobial Agents.

[52]  L. Leon,et al.  Leishmaniasis treatment: update of possibilities for drug repurposing. , 2018, Frontiers in bioscience.

[53]  Yong Sup Lee,et al.  Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents , 2018, Archives of pharmacal research.

[54]  S. Robledo,et al.  Synthesis, leishmanicidal, trypanocidal and cytotoxic activities of quinoline-chalcone and quinoline-chromone hybrids , 2017 .